Overview

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
1200 Pharma, LLC
Treatments:
Gemcitabine
Paclitaxel